chrisvoncsefalvay/vaers-outcomes huggingface dataset:
SEVERE HEADACHE FOR 3 TO 4 DAYS; This spontaneous report received from a parent concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested No concomitant medications were reported.  On an unspecified date, the patient experienced severe headache for 3 to 4 days. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from severe headache for 3 to 4 days. This report was non-serious. This case, from the same reporter is linked to 20211217508.
Pain surrounding injection site (in deltoid muscle)-could not move arm without intense pain shooting down arm.  Headache. Unable to perform normal exercise routines or sleep on affected arm as a result. Duration of symptoms: Two weeks straight following injection.  No treatment.
Patient has had cycles for about a year.   They aren't always regular timing but pretty close.  She always starts day 1 with light cramping and light bleeding with day 2-4 or 5 heavy and moderate cramping.   She should have started her cycle on 8/15 but did not.  August 6 she came in before school complaining of stomach cramps which I attributed to time for her cycle.   She also complain on the 17 & 18th  along with staying that she felt like something was wrong.  Last night she did start her cycle but immediately heavier than she's ever had and with clots and severe cramps.
Immediately had Wrist pain, body felt off within 15 minutes,  within two hours fever, body aches, injection site pain, fatigue, headache, heart racing 125bpm, chest/heart ache, after 6 hours nausea, severe arm pain, after 18 hours vomiting, body weakness, shortness of breath, almost passed out, severe bone pain, muscle aches, chills, ovary pain, break-through period .  Feet hurt to walk on, severe weakness. Pain and fever did not go away with Tylenol or Advil. Fever lasted five days. Break-through period lasted 3.5 weeks. High blood pressure was marked a week after vaccine. Still have high heart rate, shortness of breath, high blood pressure, headache, fatigue, ovary pain, malaise, swollen abdomen 4 weeks later.
sore arm, could hardly lift it by the end of the night of the vaccine, hot and chilled all night, left arm pain, right neck pain, next day slight headache, very tired, weak, winded easily, improved by the end of the next day
Mom called 10/4/05 at 2PM. States baby fussy last noc. Fever this morning 100.7 R. States she gave Motrin last noc. Fussy today. Denies redness/knots at injection site.
About a week after I noticed a red knot at the injection site. At work many other people that got the vaccine at the same time were saying they also had a knot showing up. The HR department was giving out the phone number of the clinic that gave the vaccine to anyone with side effects to call in antibiotics. I took the antibiotics with no improvement. On Nov 6th the clinic put out a letter to all employees that they were investigating the conditions. At this time I went to my normal doctor and got a round of prednisone and have completed without improvement.
Could not stand without heart rate reaching the heart attack range for 2 days. Had to crawl to the bathroom. Could not do any cardio functions for 18 months. No walking, working out, ect. Had 45 min of fitbit "active min" (over the exercise level) every night while sleeping. Assume massive myo/pericarditis but  no doctors would accept vaccine injury as an issue and no GPs within 200 miles are taking new patients within 18 months/ My current GP said no blood work for anyone overweight and if you don't starve yourself skinny they won't work with you. So I have spent a year nearly on my couch unable to walk, run, and workout. at 18 months I can manage a set of stairs without a break, so almost back to nothing. Also, according to all data I  now have -200% protection as in I am now 20% more likely to catch COVID so this was a total waste and I have ruined my entire cardiovascular system and no one will help me because all real doctors who accepted vaccine injuries have lost their license including the inventor of mRNA tech. who said you were doing it wrong.
HCP called to report inadvertent administration of expired GARDASIL 9 to a patient. Vaccine expired on 08/08/2023 and was administered on 08/14/2023. No additional AE/PQC.; HCP called to report inadvertent administration of expired GARDASIL 9 to a patient. Vaccine expired on 08/08/2023 and was administered on 08/14/2023. No additional AE/PQC.; This spontaneous report was received from a nurse and referred to a 12-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 14-AUG-2023, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (expiration date: 08-AUG-2023), administered intramuscularly for prophylaxis (strength, dose, and lot # were not provided).  The nurse reported this inadvertent administration of expired vaccine (Expired product administered). No additional adverse event or product quality complaints (No adverse event).
So, I started to have some epidermis outbreaks about a week after the second vaccine. Shortly, after that I had a poison ivy reaction, but this reaction was different in which it started to go, which is odd for poison ivy. I was having an overaction to certain irritants as well. I also would have an abnormal amount of warts that were showing up. I have a lot of epidermis outbreaks. I also have had terrible joint pains also which started a week after the second dose. I was not able to lift things or do normal activates. I am still having trouble with my joints.
With both shots I experienced the following: Migraine -3 days  Extreme fatigue  Dehydration  Nausea  Chills Hot flashes Nose bleeds with the 2nd shot. After the nose bleeds I back every tired and had a slight headache.
SUSPECTED CLINICAL VACCINE FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient via another pharmaceutical company (Pfizer) concerned a 53 year old male. Initial information was processed along with the additional information received on 20-JUN-2022. The patient's height, and weight were not reported. The patient's concurrent conditions included: asthma, cancer, and allergy. On an unspecified date, the patient previously received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (unspecified manufacturer) (suspension for injection, route of admin, and batch number: unknown, expiry: unknown) dose was not reported, 1 total was administered for prophylactic vaccination. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient received second dose of covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, route of admin not reported, batch number: 211021A and expiry: unknown) dose was not reported, 1 total, administered on 02-DEC-2021 to left arm for prophylactic vaccination. Age at time of vaccination 53 years old. Concomitant medication included: Agios 120, investigational drug for more than 6 years. On an unspecified date, the patient experienced suspected covid-19 infection and suspected clinical vaccine failure (Dose number in series 2). The patient received Paxlovid for covid-19 treatment, from 30-MAY-2022 to 04-JUN-2022. It was reported that the patient was taking unspecified other medications/products within 2 weeks of starting COVID-19 treatment. On 10-JUN-2022 at 22:00, the patient experienced rebound infection, congestion, malaise, cough and sore throat. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the suspected covid-19 infection and suspected clinical vaccine failure was not reported. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint: 90000236425.; Sender's Comments: V0- 20220636220 -COVID-19 VACCINE Ad26.COV2.S- Suspected clinical vaccination failure. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS. Therefore, this event(s) is considered not related.
Patient presented to ED with progressively worsening angioedema presumably due to either h/o heraditory angioedema, lymphoma, or in combination with recent Covid vaccine. Patient had swelling to the lips, throat, and neck. Patient had similar symptoms in the past that resolved spontaneously within a day or received ecallantide on a different occasion in 2015. Suspected angioneurotic edema per hematology and was treated with epi, Benadryl, Pepcid, Solu-medrol, and Kalbitor for HAE. No edema visualized, clear voice, and no issues with swallowing on the next day.
This spontaneous case was initially received on 09-Oct-2015. The case report was received from a Health Professional and concerns a patient with unknown age and gender. Weight: not provided, Height: not provided. For concomitant medication and therapy dates refer to the appropriate report sections. Suspect drug (s), timing and conditions surrounding the onset of reaction (s)/event (s): The patient received AFLURIA for indication protection against seasonal influenza virus on 08-Oct-2015- 08-Oct-2015, Batch no: T57505, Route of administration: Intramuscular, Dose: 0.5 ml. Additional suspect drug (s): No additional drugs suspected. Reaction (s)/ event (s) and outcome: On 08-Oct-2015, the patient experienced received an IM (intramuscular) dose of AFLURIA that had expired on 30-May-2015 (non serious, outcome: Unknown). Action taken: Discontinued. Event treatment: not provided. Rechallenge/ Dechallenge information: not applicable. For relevant test results see appropriate report section. Please add other relevant test results manually as appropriate.
This spontaneous report was received from a currently 76-year-old female patient who was reporting on herself. The patient's pertinent medical history, drug reactions and allergies were not reported. Information regarding concomitant therapies was not provided. On an unknown date, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) (dose, anatomical location, lot# and expiration date were not reported) and influenza virus vaccine (unspecified) (dose anatomical location, lot# and expiration date were not reported) both for prophylaxis. On an unknown date, the patient experienced hypersensitivity reaction. The outcome the event was unknown. The relatedness between the event and suspect therapies was not reported. This is one of two reports received from the same reporter. Sender's Comments: US-009507513-1710USA004585.
22 y/o male AD PV-2 who presented for 1 day of mild SOB and chest pain, especially with inspiration.  He admits to 1 week of URI type symptoms including nasal and chest congestion, rhinorrhea, and post-nasal drip.  Patient has just arrived overseas.  He was in processed where he received small pox vaccination on 3May 2005.  Patient subsequently transferred to duty station 06 May 2005.  Symptoms prompted sick call visit on 09 May 2005.  Treated URI symptoms with Deconamine 1 tab po q12hours, Albuterol 2 puffs q12, pericarditis treated with Indomethacin 25 mg 1 tab po tid with food x 10. Five days after receiving his 1st SPV, patient developed symptoms of chest pain, palpitations, and dyspnea. Observed overnight and treated with INDOCIN. Since then has experienced chronic CP, dyspnea and palitations
This case was reported in a literature article and described the occurrence of anaphylaxis in a 12-year-old subject of unspecified gender who was vaccinated with Influenza vaccine, manufacturer unspecified). The subject did not receive any concomitant vaccine. No egg allergy was reported in this patient. On an unspecified date the subject received unspecified dose of Influenza vaccine (unknown). Less than one day after vaccination with Influenza vaccine, the subject experienced anaphylaxis with respiratory problem (chest tightness or wheezing) and skin reactions (erythema or hives). The patient was either hospitalised or treated at the emergency ward and further referred for allergy testing. This case was assessed as medically serious by GSK. At the time of reporting the outcome of the events was unspecified. This case is linked to cases B0695450A and B0695523A. It was not possible to attribute some of the information provided in the article to one or the other patient. Therefore this report contains only the genetic information all other details can be read in the article. Summary of the article: Influenza virus infection causes substantial morbidity in children with an attendant need for healthcare utilization, school absenteeism, and secondary illness in families. Also, influenza virus can rarely lead to death in children with underlying medical conditions and in children who are otherwise healthy. Vaccination against influenza virus is the primary method for preventing influenza and its complications. The Advisory Committee on Immunization Practices' recommendations for influenza vaccination of children have expanded from the long-stand recommendation to vaccinate high-risk children aged 6 months, to vaccinating all 6- to 23-month-olds (2004), 2- to 4-year-olds (2006), and 5- to 18-year-olds (2008). The objective of the authors was to identify new or unexpected adverse events (AEs) after trivalent inactivated vaccine (TIV) in children. Methods: analysis of reports after TIV to the Vaccine Adverse Event Reporting System from 1990-2006 in children aged 2 to 17 years, and from the 2008-2009 influenza season in children aged 5 to 17 years. Empiric Bayesian data mining techniques were used to identify new or unexpected AEs during 1990-2006. Results: During 1990-2006, the Vaccine Adverse Event Reporting System received 2054 reports of children aged 2 to 17 years with a peak in the 2003-2004 influenza season. In 2008-2009, 506 reports describing 5 to 17 year olds were received. The serious reports of tests performed after TIV were approximately 10% of all reports from 2001-2006, and 6% of the reports in the 2008-2009 season. Data mining showed an increased proportion of medication errors and GUILLAIN BARRE' Syndrome (GBS). The findings of GBS could not be interpreted as causality related to vaccination. Among 201 reports of medication error, 94% had no AE reported other than the medication error itself. Conclusion: In this analysis, we found no unexpected AEs. Our review of medication error and GBS reports suggests that ongoing monitoring in these areas is appropriate.
AN EXCRUCIATING RIGHT LEG PAIN; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on JUN-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On JUN-2021, the patient experienced an excruciating right leg pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from an excruciating right leg pain. This report was non-serious.; Sender's Comments: V0-Medical assessment comment not required as per standard procedure as the case was assessed as non-serious.
if he got his 1st dose and then got Covid; if he got his 1st dose and then got Covid; This is a spontaneous report from a Pfizer-sponsored program from a contactable male consumer. A male patient of an unspecified age received bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number: Batch/Lot Number: unknown; Expiration Date: unknown), dose 1 via an unspecified route of administration on an unspecified date as SINGLE DOSE for COVID-19 immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. On an unspecified date, the patient diagnosed, if he got his 1st dose and then got covid (drug ineffective). The clinical outcome of the event was unknown. 2nd dose was scheduled for 4 weeks.   Information about Batch/Lot number has been requested. Follow-up attempts are completed. No further information is expected.
The patient experienced rash, swelling, burning sensation, pain  on her left arm (3 inches below the injection site).  She came and reported it on 9/24/21. She stated tylenol  has helped her to control the pain. We provided her with benadryl and advised her to start benadryl : 1st dose of 50mg, then may repeat if needed 25mg q4-6 hours, and apply  some ice on the burning sensation areas. We followed up with her a few hours later. she stated her conditions has improved.
nausea; vomiting; diahreaa; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Mar2021 at 13:30 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included estrogen (MANUFACTURER UKNNOWN), progesterone (MANUFACTURER UNKNOWN) and bupropion hydrochloride (WELLBUTRIN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Mar2021 at 03:00 the patient experienced nausea, vomiting and diarrhoea. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. On 24Mar2021, the patient underwent COVID-19 PCR (nasal swab) test and the result was negative. The clinical outcome of the events nausea, vomiting and diarrhoea were not recovered at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 13:30 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Slight fever, 98.7 (my normal is 97.4) Skin hurt everywhere All of my joints hurt Extreme exhaustion Nauseated Headaches (less than first shot) With first shot was nauseated for about 5 days and a headache for a week straight. BUT what is strange is, I'm getting way more hot flashes, like every hour of the day and a few times at night. When before, I would only get a hot flash maybe twice a day and none at night. All of the above symptoms went away after 2 days after the 2nd shot, except for the hot flashes, which are still affecting me, which affects my MS.
Clinician administered vaccine in which vial was diluted with 1.3ml Normal Saline rather than 1.8ml of diluent. Pt denied any side effects except for mild headache day of administration
Patient started experiencing diarrhea on same day after receiving 1st dose; All day Friday, she didn't feel like eating; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Patient started experiencing diarrhea on same day after receiving 1st dose) and DECREASED APPETITE (All day Friday, she didn't feel like eating) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy. Concomitant products included CLARITHROMYCIN (CLARITIN [CLARITHROMYCIN]) for Allergy, VITAMIN D NOS, IRON, METFORMIN, OMEPRAZOLE, CARVEDILOL, LOSARTAN, ATORVASTATIN and ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced DIARRHOEA (Patient started experiencing diarrhea on same day after receiving 1st dose) and DECREASED APPETITE (All day Friday, she didn't feel like eating). The patient was treated with BISMUTH SUBSALICYLATE, CALCIUM CARBONATE (PEPTO BISMOL [BISMUTH SUBSALICYLATE;CALCIUM CARBONATE]) at an unspecified dose and frequency. At the time of the report, DIARRHOEA (Patient started experiencing diarrhea on same day after receiving 1st dose) and DECREASED APPETITE (All day Friday, she didn't feel like eating) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Developed hives on left arm on 2/21/2020 they went away and came back on 2/22/20202 in the evening, only on left arm then have dissipated w/no intervention
This literature marketed report has been received from the authors of a published literature article title, regarding a 2 year old male patient with recurrent respiratory infections since age 6 months, hypogammaglobulinemia and atypical heterozygous Artemis mutations associated with an unrelated gene mutation (heterozygous transmembrane activator and CAML interactor (TACI) (Chromosome 17) and a heterozygous variant mutation on DNA Cross-Link Repair 1C (DCLRE1C) (Chromosome 10)). It was reported that the patient was immunodeficient. It was also stated that the patient's mother and father with an isolated TACI and Artemis mutations respectively were both asymptomatic. The patient had low serum immunoglobulin G (IgG) and normal lymphocyte subsets. On an unknown date, the patient was vaccinated with a dose of (manufacturer unknown) PPV23, injection, (dose, route of administration and injection site were not reported) and PCV13, (formulation, dose, route of administration and injection site were not reported). There were no concomitant medications reported. On an unspecified date, the patient developed failed antibody responses to PPV23 and PCV13 respectively. Genetics performed on an unspecified date revealed a variant mutation of the DCLRE1C gene of unknown significant: c.251C>G (p.S84C) and a heterozygous missense  mutation of TNFRSF13B (TACI) gene associated with common variable immunodeficiency (CVID) type 2: c.310T>C (p.C104R). The outcome of failed antibody responses to pneumococcal polysaccharide and conjugate vaccines was unknown at the time of the report. The authors considered the event to be related to PPV23 (manufacturer unknown). This is one of two reports received from the same literature article (cross referenced with MARRS# 1603USA001572). Additional information has been requested.
no bad outcome. Pt was given Bivalent Pfizer for children 5-11 yo instead of manovalent for first dose. this writer called the State of Ct and spoke to on call epidemiologist and told to just give a dose of monovalent in 2 months followed by the booster bivalent vaccine 2 months later
Nausea, chills, severe muscle aches, malaise, fatigue lasting 24 hours. Took extra strength aceteminophen which provided some relief. Soreness at injection site remains.
2 weeks after the vaccine, had vertigo after waking up. Treated this with an anti-vert medication (meclizine HCL, 25mg) that made me drowsy. The following day, still felt fatigued and had spells of feeling foggy/disassociated, ?out of it.? Unsure if this reaction was due to the medication or not.
Fever from 100.3 to 101.0 Fahrenheit, terrible headache that would not stop for 3 days, terrible joint pain and body aches, diarrhea  Symptoms lasted from March 14-March 18, 2021. Missed 3 days of work due to illness.